A dual-function XCL1-CD40L mRNA adjuvant potentiates cancer vaccines by coordinating DC recruitment and maturation
BackgroundDespite the significant promise of mRNA tumor vaccines in treating solid tumors, their clinical response rate is constrained by the low effectiveness of antigen presentation resulting from the immune-suppressive tumor microenvironment (TME). …